Hazhirkarzar Bita, Khoshpouri Pegah, Shaghaghi Mohammadreza, Ghasabeh Mounes Aliyari, Pawlik Timothy M, Kamel Ihab R
Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Surgery, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
Hepatobiliary Surg Nutr. 2020 Feb;9(1):35-48. doi: 10.21037/hbsn.2019.05.11.
One of the most common cancers worldwide, colorectal cancer (CRC) has been associated with significant morbidity and mortality and therefore represents an enormous burden to the health care system. Recent advances in CRC treatments have provided patients with primary and metastatic CRC a better long-term prognosis. The presence of synchronous or metachronous metastasis has been associated, however, with worse survival. The most common site of metastatic disease is the liver. A variety of treatment modalities aimed at targeting colorectal liver metastases (CRLM) has been demonstrated to improve the prognosis of these patients. Loco-regional approaches such as surgical resection and tumor ablation (operative and percutaneous) can provide patients with a chance at long-term disease control and even cure in select populations. Patient selection is important in defining the most suitable treatment option for CRLM in order to provide the best possible survival benefit while avoiding unnecessary interventions and adverse events. Medical imaging plays a crucial role in evaluating the characteristics of CRLMs and disease resectability. Size of tumors, proximity to adjacent anatomical structures, and volume of the unaffected liver are among the most important imaging parameters to determine the suitability of patients for surgical management or other appropriate treatment approaches. We herein provide a comprehensive overview of current-state-of-the-art imaging in the management of CRLM, including staging, treatment planning, response and survival assessment, and post-treatment surveillance. Computed tomography (CT) scan and magnetic resonance imaging (MRI) are two most commonly used techniques, which can be used solely or in combination with functional imaging modalities such as positron emission tomography (PET) and diffusion weighted imaging (DWI). Providing up-to-date evidence on advantages and disadvantages of imaging modalities and tumor assessment criteria, the current review offers a practice guide to assist providers in choosing the most suitable imaging approach for patients with CRLM.
结直肠癌(CRC)是全球最常见的癌症之一,与显著的发病率和死亡率相关,因此给医疗保健系统带来了巨大负担。CRC治疗的最新进展为原发性和转移性CRC患者提供了更好的长期预后。然而,同时性或异时性转移的存在与较差的生存率相关。转移性疾病最常见的部位是肝脏。已证明多种针对结直肠癌肝转移(CRLM)的治疗方式可改善这些患者的预后。局部区域治疗方法,如手术切除和肿瘤消融(手术和经皮),可为特定人群的患者提供长期疾病控制甚至治愈的机会。患者选择对于确定CRLM最合适的治疗方案很重要,以便在避免不必要的干预和不良事件的同时提供最佳的生存获益。医学成像在评估CRLMs的特征和疾病可切除性方面起着至关重要的作用。肿瘤大小、与相邻解剖结构的接近程度以及未受影响肝脏的体积是确定患者是否适合手术治疗或其他适当治疗方法的最重要成像参数之一。我们在此全面概述了CRLM管理中当前的先进成像技术,包括分期、治疗计划、反应和生存评估以及治疗后监测。计算机断层扫描(CT)和磁共振成像(MRI)是两种最常用的技术,可单独使用或与功能成像方式如正电子发射断层扫描(PET)和扩散加权成像(DWI)联合使用。本综述提供了关于成像方式的优缺点和肿瘤评估标准的最新证据,为临床医生选择最适合CRLM患者的成像方法提供了实践指南。